Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
Annexon Biosciences (ANNX) Stock Price & Analysis
706 Followers
ANNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.57 - $8.40
Previous Close$4.88
Volume2.88M
Average Volume (3M)1.76M
Market Cap
$444.77M
Enterprise Value$216.41M
Total Cash (Recent Filing)$259.72M
Total Debt (Recent Filing)$31.36M
Price to Earnings (P/E)-2.7
Beta1.44
Next Earnings
May 06, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding90,025,573
10 Day Avg. Volume1,928,582
30 Day Avg. Volume1,760,971
Standard Deviation0.27
R-Squared0.06
Alpha-0.00957
Financial Highlights & Ratios
Price to Book (P/B)1.67
Price to Sales (P/S)219.66
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue108.20
Enterprise Value/Gross Profit108.20
Enterprise Value/Ebitda-3.38
Forecast
1Y Price Target
$16.20Price Target Upside231.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Annexon Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsAnnexon's upcoming Phase 3 trial results for ANX005 in Guillain-Barré Syndrome offer potential for a treatment shift in the medical community, marking a significant step forward for patients and investors alike.
Drug Development ProgressAnnexon's innovative approach in early-stage ANX1502 program for neuromuscular diseases, with its oral dosing profile, sets it apart from intravenous therapies, offering convenience and a competitive edge.
Stock PerformanceAnalyst maintains a Buy rating with a positive outlook on Annexon's stock, highlighting a potential for substantial gains based on the promising data from the ANX005 program in Guillain-Barré Syndrome.
Bears Say
Clinical Trial OutcomesIf the Phase 3 trial fails, ANNX stock is predicted to decrease by 50%.
Drug EfficacyThe placebo arm for ANX005 shows a very low percentage of patients with categorical GBS-DS improvement, highlighting the treatment's necessity and potential to fill an unmet need.
Stock ValuationIf the Phase 3 trial fails, the stock is expected to be down 50% to $3-4/share.
---
Ownership Overview
21.59% Insiders
17.24% Mutual Funds
8.22% Other Institutional Investors
52.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $1.57 and its highest was $8.40 in the past 12 months.
What is Annexon Biosciences’s market cap?
Currently, no data Available
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is May 06, 2024 which is tomorrow.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Mar 26, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.436 by $0.076.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -$0.34.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 91,141,370 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.436. Following the earnings report the stock price went up 13.517%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Among the largest hedge funds holding Annexon Biosciences’s share is GMT Capital Corp. It holds Annexon Biosciences’s shares valued at 14M.
---
Annexon Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.20 (231.97% Upside)
$16.20 (231.97% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 164.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $59.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.74%
12-Months-Change
Fundamentals
Return on Equity
-55.73%
Trailing 12-Months
Asset Growth
4.41%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.
---
ANNX Stock 12 Months Forecast
Average Price Target
$16.20
▲(231.97% Upside)
Technical Analysis
Best Analysts Covering ANNX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+14.43%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +14.43% per trade.
---